Mass cytometry: A high-throughput platform to visualize the heterogeneity of acute myeloid leukemia

Abstract

Behbehani and colleagues use mass cytometry to profile the heterogeneity of acute myeloid leukemia (AML) as compared with normal hematopoiesis. By using this approach and characterizing leukemic stem cells, important differences in response to chemotherapy between AML subsets can potentially be explained and new targeted approaches considered.